Elizabeth H. Stover, MD, PhD, on Ovarian Cancer: Nivolumab Plus Bevacizumab for Relapsed Disease

August 13, 2020 By The ASCO Post Staff

Elizabeth H. Stover, MD, PhD, of Dana-Farber Cancer Institute, discusses an analysis of genomic alterations in patients with relapsed ovarian cancer who were treated with nivolumab plus bevacizumab in a phase II clinical trial. The study was conducted to identify potential biomarkers of response (Abstract 1048).

Related Content